CDK12 (E8G6X) Rabbit mAb #45791
- WB
- IP
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 205 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
Storage
Protocol
Specificity / Sensitivity
CDK12 (E8G6X) Rabbit mAb recognizes endogenous levels of total CDK12 protein. Based on the sequence of the peptide antigen, this antibody is expected to detect all isoforms of CDK12. By western blot, this antibody detects bands of unknown origin at approximately 100 and 150 kDa.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala497 of human CDK12 protein.
Background
Cyclin-dependent kinase 12 (CDK12/CRKRS/CRK7) is composed of a central CTD kinase domain, several proline-rich regions, and several amino-terminal arginine/serine (RS) motifs common to splicing factors (1). CDK12 is ubiquitously expressed and forms a complex with cyclin K that regulates phosphorylation of the C-terminal domain (CTD) of RNA polymerase II (1-4). CDK12 is important for expression of a subset of long genes with high numbers of exons including some regulators of the DNA damage response, such as breast and ovarian cancer type 1 susceptibility protein 1 (BRCA1) and ataxia telangiectasia and Rad3-related (ATR) (3). Depletion of CDK12 results in spontaneous DNA damage and increased sensitivity to DNA damage agents (3). Research studies have shown that CDK12 is recurrently mutated in high-grade ovarian cancer (5,6). In addition, high levels of CDK12 are required to maintain pluripotency of embryonic stem cells (7).
- Ko, T.K. et al. (2001) J Cell Sci 114, 2591-603.
- Bartkowiak, B. et al. (2010) Genes Dev 24, 2303-16.
- Blazek, D. et al. (2011) Genes Dev 25, 2158-72.
- Cheng, S.W. et al. (2012) Mol Cell Biol 32, 4691-704.
- The Cancer Genome Atlas Research Network (2011) Nature 474, 609-15.
- Carter, S.L. et al. (2012) Nat Biotechnol 30, 413-21.
- Dai, Q. et al. (2012) J Biol Chem 287, 25344-52.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.